A REVIEW ON THE DEVELOPMENT OF FAVIPRAVIR AGAINST SARS COV 2 INFECTION
DOI:
https://doi.org/10.22159/ijcpr.2022v14i2.1957Keywords:
Favipravir, Sars Cov 2, Drug Repurposing, Purine nucleoside, Chemical synthesis, Clinical trials, FPVAbstract
Covid 19, the disease first identified in the Chine city of Wuhan in December 2019 had been declared as a pandemic by WHO. This pandemic caused by Sars Cov 2 has resulted in 165.5 million infections and 3.5 million deaths globally, as of now. Till now no drug isavailable to fight against this deadly disease. The strategy adopted by drug discovery groups is drug repurposing which has not met much success with chloroquine as well as remdesivir. A relatively new candidate in the fray is favipravir which was originally developed by Toyama chemical company against influenza strains. Few synthetic routes are developed for this compound and the safety concerns are relatively few. If favourable results from the ongoing clinicaltrials arise, that may provide the therapeutic community a lethalweapon against the virus.
Downloads
References
Mohan BS, Vinod N. COVID-19: An Insight into SARS-CoV2 Pandemic Originated at Wuhan City in Hubei Province of China. J Infect Dis Epidemiol. 2020;6(4):146. doi: 10.23937/2474-3658/1510146.
Zhao GP. SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Philos Trans R Soc Lond B Biol Sci. 2007;362(1482):1063-81. doi: 10.1098/rstb.2007.2034, PMID 17327210.
Sharma A, Garcia G, Wang Y, Plummer JT, Morizono K, Arumugaswami V, Svendsen CN. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep Med. 2020. July 21;1(4):100052. doi: 10.1016/j.xcrm.2020.100052.
Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, Atif SM, Hariprasad G, Hasan GM, Hassan MI. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165878. doi: 10.1016/j.bbadis.2020.165878. PMID 32544429.
V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155-70. doi: 10.1038/s41579-020-00468-6, PMID 33116300.
Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and Coronavirus Disease 2019: What we know so far. Pathogens. 2020;9(3):231-8. doi: 10.3390/ pathogens9030231, PMID 32245083.
Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev. 2020;33(4):e00028-20. doi: 10.1128/CMR.00028-20, PMID 32580969.
Simabuco FM, Tamura RE, Pavan ICB, Morale MG, Ventura AM. Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses. Genet Mol Biol. 2020;44(1) Suppl 1:e20200212. doi: 10.1590/1678-4685-GMB-2020-0212. PMID 33237152.
Feng TS, Liu DX. Human coronavirus: Host-Pathogen Interaction. Annu Rev Microbioogy. 2019 Sep 8;73:529-57. doi: 10.1146/annurev-micro-020518-115759, PMID 201973.
Haque SM, Ashwaq O, Sarief A, Azad John Mohamed AK. A comprehensive review about SARS-CoV-2. Future Virol. 2020;15(9):625-48. doi: 10.2217/fvl-2020-0124, PMID 33224265.
Robson B. COVID-19 coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed Achilles’ heel conserved region to minimize probability of escape mutations and drug resistance. Comput Biol Med. 2020;121:103749. doi: 10.1016/j.compbiomed.2020.103749.
Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72(6):1479-508. doi: 10.1007/s43440-020-00155-6, PMID 32889701.
Seifi T, Kamali RA. Antiviral performance of graphene-based materials with emphasis on COVID-19: a review, medicine in. Drug Discov. 2021;11. doi: 10.1016/j.medidd.2021,100099. PMID 100099.
Arora G, Shrivastava R, Kumar P, Bandichhor R, Krishnamurthy D, Sharma R, Matharu A, Pandey J, Rizwan M. Recent advances made in the synthesis of small drug molecules for clinical applications: an insight. Current Research in Green and Sustainable Chemistry. 2021;4:100097.
Zhu W, Chen C, Gorshkov K, Xu M, Donald C. Zheng W. RNA-dependent RNA polymerase as a target for COVID-19. Drug Discov. 2021;25(10):1141-51.
Antonov L. Favipiravir tautomerism: A short theoretical report. ChemRxiv; 2020. Available from: https://doi.vol.1.doi: 10.26434/chemrxiv.12115620.
Goloveshkin AS, Korlyukov AA, Vologzhanina AV. Novel polymorph of favipiravir-an antiviral medication. Pharmaceutics. 2021;13(2):139-46. doi: 10.3390/ pharmaceutics13020139, PMID 33494498.
Guo Q, Xu M, Guo S, Zhu F, Xie Y, Shen J. The complete synthesis of favipiravir from 2-aminopyrazine. Chem Pap. 2019;73(5):1043-51. doi: 10.1007/s11696-018-0654-9.
Bocan TM, Basuli F, Stafford RG, Brown JL, Zhang X, Duplantier AJ, Swenson RE. Synthesis of 18F favipiravir and biodistribution in C3H/HeN mice as assessed by positron emission tomography. Sci Rep. 2019;9(1):1785. doi: 10.1038/s41598-018-37866-z, PMID 30741966.
Titova YA, Fedorova OV. Favipiravir- a modern antiviral drug: synthesis and modifications. Chem Heterocycl Compd (N Y). 2020;56(6):659-62. doi: 10.1007/s10593-020-02715-3, PMID 32836314.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Japan Acad Ser B Phys Biol Sci. 2017;93(7):449-63. doi: 10.2183/ pjab.93.027, PMID 28769016.
Aftab SO, Ghouri MZ, Masood MU, Haider Z, Khan Z, Ahmad A, Munawar N. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J Transl Med. 2020;18(1):275. doi: 10.1186/s12967-020-02439-0, PMID 32635935.
Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020;76(4):370-6. doi: 10.1016/j.mjafi.2020.08.004.
Vora A, Tiwaskar M. Favipiravir. J Assoc Physicians India. 2020 Aug;68(8):91-2. PMID 32738849.
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Role of favipiravir in the treatment of COVID-19, Int Nat J Infect Dis. 2021;102:501-8.
Yaylaci S, Dheir H, Şenocak D, Genc AB, Kocayigit H, Çekiç D, Varım C, Aydın A, Koroglu M, Karabay O. The effects of favipiravir on hematological parameters of covıd-19 patients. Rev Assoc Med Bras. 2020;66 Suppl 2:65-70. doi: 10.1590/1806-9282.66.s2.65.
Lemaitre F, Solas C, Gregoire M, Lagarce L, Elens L, Polard E, Saint-Salvi B, Sommet A, Tod M, Barin-Le Guellec C. French society of pharmacology, therapeutics (SFPT), the international association of therapeutic drug monitoring, clinical toxicology (IATDMCT). Potential drug–drug interactions associated with drugs currently proposed for COVID‐19 treatment in patients receiving other treatments. Fundam Clin Pharmacol. 2020;34(5):530-47. doi: 10.1111/fcp.12586, PMID 32603486.
Driouich JS, Cochin M, Lingas G. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat Commun 2021;12:173. doi: 10.1038/s41467-021-21992.
Takahashi H, Iwasaki Y, Watanabe T, Kobayashi T, Moriyo M, Ichinose N, Okada Y, Oiwa A, Oda T. Case studies of Sars cov-2 treated with favipravir among patients in critical or severre condition, Int Nat J Infect Dis. 2020;100:283-5.
Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, Soliman S, Elbahnasawy M, Badawi R, Tageldin MA. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021;166(3):949-54. doi: 10.1007/s00705-021-04956-9, PMID 33492523.
Published
How to Cite
Issue
Section
Copyright (c) 2022 VINOD B.
This work is licensed under a Creative Commons Attribution 4.0 International License.
